Mesoblast Limited carries a market capitalization of 2.00B, placing it among publicly traded companies globally.
| Market Cap | 2.00B |
| Enterprise Value | N/A |
Mesoblast Limited maintains a current ratio of 3.57, meaning it holds 3.6x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 3.57 |
| Quick Ratio | 3.07 |
| Debt / Equity | 44.97 |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Mesoblast Limited's stock has gained approximately 59.79381% over the past 52 weeks. The 50-day moving average sits at 1.65, while the 200-day moving average is 1.60.
| Beta (5Y) | N/A |
| 52-Week Price Change | 59.79381% |
| 50-Day Moving Average | 1.65 |
| 200-Day Moving Average | 1.60 |
| Average Volume (20 Days) | N/A |
| Operating Cash Flow | N/A |
| Capital Expenditures | -1.33M |
| Free Cash Flow | -1.33M |
| FCF Per Share | N/A |
Mesoblast Limited's most recent stock split took place on December 11, 2023 with a 500:527 split ratio.
| Last Split Date | 12/11/2023 |
| Split Ratio | 500:527 |
Mesoblast Limited posts an Altman Z-Score of -12.55, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -12.55 |